Stable Liquid Formulation Of Amg 416 Hcl (Etelcalcetide)

Patent No. EP3246017 (titled "Stable Liquid Formulation Of Amg 416 Hcl (Etelcalcetide)") was filed by Amgen on Jun 27, 2014. The application was issued on Mar 24, 2021.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ADALVODec 22, 2021SLAVIK
STADA ARZNEIMITTELDec 22, 2021HAMM & WITTKOPP
SYNTHONDec 22, 2021HAMM & WITTKOPP
FRESENIUS KABI DEUTSCHLANDDec 21, 2021FRESENIUS KABI DEUTSCHLAND

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3246017

AMGEN
Application Number
EP17160312A
Filing Date
Jun 27, 2014
Status
Granted And Under Opposition
Feb 19, 2021
Publication Date
Mar 24, 2021